Mouse Phosphotylinosital 3 kinase,PI3K ELISA Kit

Code CSB-E08419m
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
phosphoinositide-3-kinase, catalytic, alpha polypeptide
Alternative Names
Pik3ca ELISA Kit; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform ELISA Kit; PI3-kinase subunit alpha ELISA Kit; PI3K-alpha ELISA Kit; PI3Kalpha ELISA Kit; PtdIns-3-kinase subunit alpha ELISA Kit; EC 2.7.1.153 ELISA Kit; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha ELISA Kit; PtdIns-3-kinase subunit p110-alpha ELISA Kit; p110alpha ELISA Kit; Phosphoinositide-3-kinase catalytic alpha polypeptide ELISA Kit; Serine/threonine protein kinase PIK3CA ELISA Kit; EC 2.7.11.1 ELISA Kit
Abbreviation
PIK3CA
Uniprot No.
Species
Mus musculus (Mouse)
Sample Types
serum, plasma, tissue homogenates
Detection Range
23.5 pg/mL-1500 pg/mL
Sensitivity
5.8 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cancer
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of mouse PI3K in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 102
Range % 95-106
1:2 Average % 102
Range % 96-107
1:4 Average % 87
Range % 83-92
1:8 Average % 95
Range % 89-99
Recovery
The recovery of mouse PI3K spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 97 92-101
EDTA plasma (n=4) 102 93-105
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
1500 2.725 2.812 2.769 2.625
750 2.020 2.165 2.093 1.949
375 1.514 1.565 1.540 1.396
187.5 1.014 1.023 1.019 0.875
94 0.614 0.665 0.640 0.496
47 0.384 0.392 0.388 0.244
23.5 0.271 0.277 0.274 0.130
0 0.143 0.144 0.144  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Mouse PIK3CA ELISA Kit was designed for the quantitative measurement of Mouse PIK3CA protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 23.5 pg/mL-1500 pg/mL and the sensitivity is 5.8 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Also has serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS. Plays a role in the positive regulation of phagocytosis and pinocytosis.
Gene References into Functions
  1. miR152 may have an important role in pancreatic beta cell function, and established an association between miR152 and the PI3Kalpha axis. PMID: 30106118
  2. H1047R mutation of Pik3ca induces centrosome amplification in cultured mouse cells. PMID: 29170395
  3. The crucial role of p110beta and the more subtle role of p110alpha in the production of PIP3 molecular species following platelet stimulation has been demonstrated. PMID: 29902570
  4. Here, we describe a role for PI3K/AKT in the regulation of TRF1, an essential component of the shelterin complex. PI3K and AKT chemical inhibitors reduce TRF1 telomeric foci and lead to increased telomeric DNA damage and fragility. We identify the PI3Kalpha isoform as responsible for this TRF1 inhibition. PMID: 29097657
  5. The data establish oncogenic PIK3CA mutations as a cause of glutamine dependency in colorectal cancer. PMID: 27321283
  6. High PI3k expression is associated with gastrointestinal stromal tumor. PMID: 28923937
  7. High PI3K expression is sensitive to initial injury intensity induced by freeze damage. PMID: 27647425
  8. excessive proliferation of endometrial epithelial cells was observed in Pik3cad/d mice. Our studies suggest that Pik3ca has a critical role in uterine gland development and female fertility PMID: 29346447
  9. Long latency DMBA induced mouse mammary tumors reproduce the molecular profile of human luminal breast carcinomas, displaying a high incidence of activating Pik3caH1047 and loss of function Pten mutations. PMID: 27588403
  10. Data show that the phosphoinositide 3-kinase (PI3K) inhibitor BKM120 led to a precipitous drop in DNA synthesis within 8 h of drug treatment, whereas DNA synthesis in normal tissues was less affected. PMID: 27402769
  11. Using genetic inactivation of the growth and metabolism regulator, Pik3ca (encoding PIK3CA also known as p110alpha, alpha/+), the interplay between the maternal genome and the fetal genome on placental phenotype, was examined. PMID: 27621448
  12. Data suggest a critical role for KDM3A in the PI3K/AP-1 oncogenic axis and propose a novel strategy for inhibition of KDM3A against liver tumor development under PI3K pathway activation. PMID: 28692045
  13. Data show that tumors lacking PSMA had less than half the abundance of type 1 insulin-like growth factor receptor (IGF-1R), less activity in the survival pathway mediated by PI3K-AKT signaling, and more activity in the proliferative pathway mediated by MAPK-ERK1/2 signaling. PMID: 28292957
  14. Both PIK3CA mutants H1047R and E545K are able to activate the AKT/mTOR pathway. An intact AKT2/mTOR complex 1 cascade is required for tumourigenesis induced by H1047R/c-Met or E545K/c-Met in the liver in mice. PMID: 26716908
  15. We further demonstrate that loss of one allele of PTEN is sufficient to shift isoform dependency from p110alpha to p110beta in vivo. These results provide insight into the molecular mechanism by which ErbB2-positive breast cancer escapes p110alpha inhibition. PMID: 28783168
  16. Studies indicate that the Pten+/- genotype displayed neoplasia in multiple organs, including the endometrium and that the Pten is a key regulatory player in the PI3K/PTEN/AKT pathway. PMID: 27910071
  17. Data show that docetaxel, rapamycin and tanespimycin multi-drug loaded micelles targeted against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer. PMID: 28350865
  18. Data show that macrophage M2 polarization was mediated through PTEN/PI3k/AKT pathway activation. PMID: 28273403
  19. Constitutive Activation of PI3K is associated with Ovarian Granulosa Cell Tumors. PMID: 27197196
  20. Together with recent identification of somatic mutations in p110a (encoded by PIK3CA), our data establish a potential mechanistic link between AGGF1 and PIK3CA, the two genes identified for Klippel-Trenaunay syndrome (KTS) PMID: 27522498
  21. p110beta has a role in mediating skeletal muscle metabolic signaling by regulating expression of AMP-activated protein kinase PMID: 27965101
  22. The mRNA levels of leptin and of 17-beta-dehydrogenase 3, and enzyme important for testosterone production, were significantly higher in the testis of adult alpha-/- males( PI3K catalytic subunit p110alpha deletion). PMID: 28357399
  23. PI3K signaling plays a modulatory role in the regulation of the transcriptional rhythm of the Dbp gene by targeting BMAL1 and CLOCK. PMID: 27022680
  24. Analysis of 18 signalling signatures revealed that PI3K signalling is significantly induced whereas EGFR signalling is significantly reduced in Pten() versus PIK3CA(H1047R) tumors. Thus, Pten() and PIK3CA(H1047R) tumors exhibit discernable differences that may impact tumorigenesis and response to therapy. PMID: 26814435
  25. activating PIK3CA mutations gives rise to sporadic venous malformations in mice, which closely resemble the histology of the human disease. PMID: 27030594
  26. These data demonstrate a causal relationship between activating Pik3ca mutations and the genesis of vascular malformations. PMID: 27030595
  27. data demonstrate that the PI3K p110alpha-Akt/Rac1 and NOX1 signalling pathways play a pivotal role in VEGF-induced vascular differentiation and cell migration. PMID: 26553657
  28. miR-490-5p functions as a tumour suppressor in renal carcinoma by targeting PIK3CA PMID: 26559013
  29. Reelin thus plays a role in restraining RAS and PI3-kinase promotion of cell motility and potentially tumour metastasis. PMID: 27071537
  30. Chronic CoQ(10) supplementation attenuates aspects of diabetic cardiomyopathy, even in a setting of reduced cardiac PI3K(p110alpha) protective signaling PMID: 25937176
  31. A subgroup of colon cancers might arise in the setting of activated PI3K, as seen in a PIK3CA mutant mouse model. PMID: 26863299
  32. p110a as well as p110d Class IA PI3Ks are important to immune regulation; inhibition of both subunits may be an effective therapeutic approach in inflammatory autoimmune diseases like rheumatoid arthritis. PMID: 26883061
  33. Interestingly, we observed that IRGM1 enhanced F-actin polymerization and triggers epithelial mesenchymal transition (EMT) through a mechanism involved in PIK3CA mediated Rac1 activation. PMID: 26202910
  34. Study demonstrates the oncogenic cooperation between PI3K and Yap pathways along liver carcinogenesis. The PIK3CA/Yap mouse represents an important preclinical liver tumor model. PMID: 25826091
  35. Data show that the RNA-binding protein lin28a/microRNA let-7a axis regulated glucose metabolism in part through the insulin-PI3K-mTOR pathway. PMID: 25688987
  36. ARID1A and PIK3CA mutations cooperate to promote tumour growth through sustained IL-6 overproduction. PMID: 25625625
  37. Cone-specific deletion of p110alpha resulted in cone degeneration. PMID: 25742742
  38. Pten and Pik3ca have distinct consequences on the activation of the phosphatidylinositol 3-kinase pathway in endometrial epithelium. PMID: 25698082
  39. Hepatic expression of p110alpha containing hot spot mutations results in rapid hepatic steatosis, paradoxically accompanied by increased glucose tolerance, and marked glycogen accumulation. PMID: 26169833
  40. Results show that PI3Kalpha does not directly regulate myocardial contractility, but is required for recovery from tamoxifen/Cre toxicity. PMID: 25618408
  41. Data indicate that the effects of irisin were abolished by the inhibition of phosphoinositide 3-kinase (PI3K) p110alpha subunit and the phosphorylation of Akt/protein kinase B. PMID: 26201094
  42. miR-378 inhibits hepatic insulin signalling through targeting Pik3ca. PMID: 25471065
  43. oncogenic Pik3ca(H1047R) activates a multipotent genetic program in normally lineage-restricted populations at the early stage of tumour initiation, setting the stage for future intratumoural heterogeneity PMID: 26266985
  44. Study shows that both ubiquitous and endothelial cell-specific expression of the Pik3caH1047R mutation during embryonic development lead to severe vascular malformations that result in lethality prior to E10.5. PMID: 25958091
  45. expression of the Pik3ca(H1047R) mutation throughout the body resulted in a dramatic increase in body weight within 3 weeks of induction, which was associated with increased organ size rather than adiposity PMID: 25550458
  46. 2 PDX models showed gained mutations such as PIK3CA or FBWX7 mutation. Ten patient-derived advanced colon cancer xenograft models were established. PMID: 25526474
  47. functional interaction of RAS with p110alpha in host tissue was required for efficient establishment and growth of metastatic tumors PMID: 25003191
  48. Data indicate cellular repressor of E1A-stimulated gene (CREG) as a factor in regulating endothelial differentiation and vasculogenesis via VEGF/PI3K/Akt pathway. PMID: 24896346
  49. Pancreas-specific disruption of Pik3ca or Rac1, but not Pik3cb, prevented the development of pancreatic tumors in Kras(G12D/+);Ptf1a(Cre/+) mice. PMID: 25311989
  50. Prostate tumor driven by polyomaviruses MT depends on p110alpha but not p110beta. PMID: 24991009

Show More

Hide All

Protein Families
PI3/PI4-kinase family
Database Links
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1